Emily Gwyer Findlay (Emily L Gwyer Findlay)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Venues

Discovery immunology

Blood

PLoS pathogens

Nature communications

University of Edinburgh

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Edinburgh Jan 01 2017

United Kingdom

Fellow; Royal Society Dorothy Hodgkin Fellow :: Centre for Inflammation Research

University of Edinburgh Feb 01 2012 - Dec 31 2016

United Kingdom

Postdoctoral research fellow :: Centre for Inflammation Research

London School of Hygiene and Tropical Medicine Sep 01 2008 - Jan 31 2012

United Kingdom

Post doctoral fellow :: Department of Immunology

Publications

Philip P Ahern, Emily Gwyer Findlay
Adapting for success: T cell features at tissue sites. Discovery immunology 3 (1) (2024)
Angus Moffat, Emily Gwyer Findlay
Evidence for antigen presentation by human neutrophils. Blood 143 (24) (2024)
Angus Moffat, Emily Gwyer Findlay
Evidence for antigen presentation by human neutrophils. Blood 143 (24) (2024)
Katie J Smith, Danielle Minns, Brian J McHugh, Rebecca K Holloway, Richard O'Connor, Anna Williams, Lauren Melrose, Rhoanne McPherson, Veronique E Miron, Donald J Davidson, Emily Gwyer Findlay
The antimicrobial peptide cathelicidin drives development of experimental autoimmune encephalomyelitis in mice by affecting Th17 differentiation. PLoS biology 20 (8) (2022)
Katie J Smith, Emily Gwyer Findlay
Expression of antimicrobial host defence peptides in the central nervous system during health and disease. Discovery immunology 1 (1) (2022)
Katie J Smith, Emily Gwyer Findlay
Expression of antimicrobial host defence peptides in the central nervous system during health and disease. Discovery immunology 1 (1) (2022)
Danielle Minns, Katie J Smith, Virginia Alessandrini, Gareth Hardisty, Lauren Melrose, Lucy Jackson-Jones, Andrew S MacDonald, Donald J Davidson, Emily Gwyer Findlay
The neutrophil antimicrobial peptide cathelicidin promotes Th17 differentiation. Nature communications 12 (1) (2021)
Emily Gwyer Findlay, Greg Sutton, Gwo-Tzer Ho
The MARVEL trial: a phase 2b randomised placebo-controlled trial of oral MitoQ in moderate ulcerative colitis. Immunotherapy advances 1 (1) (2020)
Danielle Minns, Katie Jane Smith, Emily Gwyer Findlay
Orchestration of Adaptive T Cell Responses by Neutrophil Granule Contents. Mediators of inflammation 2019 (2019)
Brian J McHugh, Rongling Wang, Hsin-Ni Li, Paula E Beaumont, Rebekah Kells, Holly Stevens, Lisa Young, Adriano G Rossi, Robert D Gray, Julia R Dorin, Emily Gwyer Findlay, David Brough, Donald J Davidson
Cathelicidin is a "fire alarm", generating protective NLRP3-dependent airway epithelial cell inflammatory responses during infection with Pseudomonas aeruginosa. PLoS pathogens 15 (4) (2019)

Emily Gwyer Findlay.css-eqlu8i{font-size:small;padding-left:4px;} (Emily L Gwyer Findlay)

Publication Activity (10 Years)

Top Topics

Top Venues

Emily Gwyer Findlay (Emily L Gwyer Findlay)